insiderwall
Menu
SuperinvestorInsider
First Tracks Biotherapeutics, Inc. TRAXV

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing immunology therapeutics targeting autoimmune and inflammatory diseases. The company focuses on advancing innovative treatments within the immunology sector, addressing unmet medical needs in conditions characterized by

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees0
TickerTRAXV

Statistics

Market Cap$613.5M
Revenue (TTM)$0
Net Income-$163.7M
Net Margin
EPS
P/E
P/S
P/B2.38
EV/EBITDA-2.83
ROE-41.8%
Dividend Yield
Price$17.66

Data: Twelve Data · Revenue = mcap / P/S

First Tracks Biotherapeutics, Inc. (TRAXV) — Azioni, fondamentali e superinvestor | InsiderWall